APPLIKATIONSBEHÄLTER

European patent · EP3819231 · In force

Register entry

Publication number
EP3819231
Application number
EP19812624
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
May 27, 2019
Published
May 12, 2021
Granted
Jan 10, 2024
Protection ends at the latest
May 26, 2039
Next annual fee due
May 31, 2027
IPC classes
A45D 34/04 (2006.01)
B65D 47/42 (2006.01)
B43K 1/12 (2006.01)
B43K 5/18 (2006.01)
B43K 8/12 (2006.01)
B43K 23/12 (2006.01)
B43M 11/06 (2006.01)
Priority
JP 2018105125 31.05.2018
JP 2018135943 19.07.2018
PCT application
PCT/JP2019/020799 27.05.2019
PCT publication
WO2019/230619 05.12.2019
Filing language
Japanese
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jun 1, 2026

    Change

    Published in Swissreg on 01.06.2026

  2. Jun 1, 2025

    Change

    Published in Swissreg on 01.06.2025

  3. Nov 20, 2024

    Change

    Published in Swissreg on 20.11.2024

  4. Jun 2, 2024

    Change

    Published in Swissreg on 02.06.2024

  5. Apr 3, 2024

    Agent entered

    Representative
    Novagraaf International SA, Chemin de l'Echo 3, 1213 Onex

    Published in Swissreg on 03.04.2024

  6. Jan 10, 2024

    Granted

    Published in Swissreg on 10.01.2024

Parties

Holder

Sato Pharmaceutical Co., Ltd.

5-27 Motoakasaka 1-chome Minato-ku, Tokyo 107-0051, JP

Agent

Novagraaf International SA

Chemin de l'Echo 3, 1213 Onex

Inventor

SAKATA Kota

Tokyo 136-8531, JP

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.